Tirzepatide (sodium salt)
CAY-39748-5 5 mg
Data Sheet: 
SDS:
SDS:
Formulation
A solid
Purity
≥95%
MW
4813,5
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A dual GLP-1R and GIP receptor agonist; induces cAMP production in HEK293 cells expressing human GLP-1R or human GIP receptor (EC50s = 6.54 and 1.01 nM, respectively); induces receptor internalization in HEK293 cells expressing human GLP-1R or GIP receptor at 100 nM; decreases body weight, food intake, plasma levels of leptin, triglycerides, and FFAs, hepatic levels of triglycerides, and blood glucose levels in a mouse model of high-fat diet-induced obesity at 10 nmol/kg per day; prevents A. alternata-induced increases in the numbers of eosinophils and lymphocytes levels in the BALF from A. alternata-challenged mice at 50 nmol/kg every three days; inhibits methacholine-induced bronchoconstriction in a mouse model of diabetes-induced asthma at 50 nmol/kg every three days
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
